BAY-2402234 NEW
| Price | $183 | $259 | $387 |
| Package | 1mg | 2mg | 5mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-08 |
Product Details
| Product Name: BAY-2402234 | CAS No.: 2225819-06-5 |
| Purity: 99.67% | Supply Ability: 10g |
| Release date: 2026/06/08 |
Product Introduction
Bioactivity
| Name | BAY-2402234 |
| Description | BAY-2402234 is an inhibitor of dihydroorotate dehydrogenase (DHODH) for the treatment of myeloid malignancies.BAY 2402234 is a selective low-nanomolar inhibitor of human DHODH enzymatic activity. |
| In vitro | BAY-2402234 induces differentiation of AML cell lines also in a sub-nanomolar to low-nanomolar range which demonstrates the anticipated mode of action in cellular mechanistic assays[1]. BAY-2402234 is a selective low-nanomolar inhibitor of human DHODH enzymatic activity. It potently inhibits proliferation of AML cell lines in the sub-nanomolar to low-nanomolar range in vitro. |
| In vivo | BAY-2402234 demonstrates potent in vivo anti-tumor effectiveness as a single agent across various AML (acute myeloid leukemia) xenograft models, including subcutaneous, disseminated, and patient-derived (PDX) forms. It promotes AML cell differentiation, evident through increased differentiation cell surface markers in treated xenograft and PDX models. The engagement of this novel DHODH (dihydroorotate dehydrogenase) inhibitor is confirmed by elevated dihydroorotate levels in tumor tissues and plasma post-treatment. Additionally, transcriptomic analyses reveal differentiation-related changes after a single dose of BAY-2402234, underscoring its mechanistic impact on AML cells[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : < 10 mg/mL (19.2 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. DMSO : 150 mg/mL (288 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (19.2 mM), Solution. |
| Keywords | RNASynthesis | RNA Synthesis | Inhibitor | inhibit | DNASynthesis | DNA/RNA Synthesis | DNA Synthesis | Dihydroorotate Dehydrogenase | DHODH | BAY-2402234 | BAY2402234 | BAY 2402234 |
| Inhibitors Related | 5-Fluorouracil | Adenine hemisulfate | Guanidine hydrochloride | Hexane-1,6-diol | Benzyl alcohol | 2-Methylaminoethanol | 2,4-D | Adenine | 1,4-Naphthoquinone | Carbazole | Thymidine | Usnic Acid |
| Related Compound Libraries | Mitochondrial Membrane Protein-Targeted Compound Library | Bioactive Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Metabolism Disease Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $98.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-01 | |
| $2580.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-19 | |
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-26 | ||
| $183.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-08 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY